Sigma-Tau grants Pierre Fabre exclusive license for antimalarial Eurartesim in 32 African countries

3 July 2015

Eurartesim (dihydroartemisinin/piperaquine), a drug granted marketing authorization in Europe in 2012, has been exclusively licensed to French privately-held drugmaker Pierre Fabre in 32 African countries by Italy’s Sigma-Tau, part of the ALFASIGMA group.

Pierre Fabre will register, distribute and promote Eurartesim in Senegal, Guinea, Mali, Ivory Coast, Burkina Faso, Niger, Madagascar, Togo, Benin, RDC, Congo, Chad, Gabon, Cameroon, Mauritania, Burundi, Nigeria, Ghana, Kenya, Tanzania, Uganda, Angola, Ethiopia, Malawi, Liberia, Sierra Leone, Mozambique, Zambia, Zimbabwe, Botswana, Swaziland and Namibia. No financial terms of the accord were disclosed.

Eurartesim is a fixed-dose artemisinin-based combination therapy (ACT) comprising dihydroartemisinin and piperaquine. In endemic areas, associations allow the complete disappearance of the parasite faster than other antimalarial drugs and are therefore recommended by the World Health Organization to limit the emergence of resistant plasmodium strains.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK